Lobachevsky University scientists synthesize a new compound with anti-tumor properties

February 02, 2018

A research team of the UNN Faculty of Chemistry led by Professor Alexei Fedorov has developed and synthesized a new multifunctional compound that possesses anti-tumor properties that are due to several independent effects. The active compound is a conjugate of a photoactive organic dye (photosensitizer), a derivative responsible for selective delivery of the medicine to tumor tissues and targeted therapy (biological vector), a linker, and special groups that increase the water solubility of the entire compound (hydrophilizing fragments).

The photosensitizer is a modified natural compound, a chlorin-?6 derivative obtained from methyl pheophorbide ?, which in turn has been synthesized from chlorophyll ?, commonly known as a compound that gives the green coloring to most plants. The biological vector used in this work is a ligand for epithelial growth factor receptors (EGFR) and vascular endothelium growth factor receptors (VEGFR). The vector also acts as a tyrosine kinase inhibitor. Its action is based on the selective binding with growth factor receptors, specific glycoproteins that are expressed in an abnormally large amount on the surface of tumor cells. Thus, the presence of growth factor ligands in the compound allows it to selectively accumulate in the tumor tissue. The linker used in the compound is 1,2,3-triazole, a biorthogonal functional group that was obtained by the "click chemistry" reaction - a modern approach to the synthesis of many biocompatible compounds. It can be noted that one of the scientists who stood at the origins of click chemistry is Professor Valery Fokin, a former graduate of Lobachevsky University of Nizhny Novgorod (UNN). The chemical structure of the compound also includes some groups that increase the compound's solubility in aqueous solutions, which is necessary for delivering drugs to tumor cells through the bloodstream.

Biological research performed by the group headed by Associate Professor Irina Balalaeva (UNN Institute of Biology and Biomedicine) confirmed the new compound's effectiveness. The researchers proved the selectivity of multifunctional conjugate accumulation on various lines of tumor cells. A more significant therapeutic effect is observed for cell lines with increased expression of growth factor receptors. Biological studies on model animals demonstrated highly selective accumulation in tumor tissue. At the same time, practically zero content of the drug in other tissues of the body was observed. Investigations of light and dark activity were carried out. Light activity was shown to be at the level of 10-5 - 10-6 mol/l, which is an order of magnitude lower than the dark activity of 10-4 mol/l.

At present, further research is continuing in this direction.

Lobachevsky University

Related Tumor Cells Articles from Brightsurf:

A more sensitive way to detect circulating tumor cells
Breast cancer is the most frequently diagnosed cancer in women, and metastasis from the breast to other areas of the body is the leading cause of death in these patients.

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

How to prevent the spread of tumor cells via the lymph vessels
Scientists from the German Cancer Research Center and the Mannheim Medical Faculty of the University of Heidelberg identified a new way to block the dangerous spread of tumor cells via lymphatic vessels.

The CNIO reprograms CRISPR system in mice to eliminate tumor cells without affecting healthy cells
CNIO researchers destroyed Ewing's sarcoma and chronic myeloid leukaemia tumor cells by using CRISPR to cut out the fusion genes that cause them.

Feeding off fusion or the immortalization of tumor cells
Despite all recent progress, cancer remains one of the deadliest human diseases.

How do tumor cells divide in the crowd?
Scientists led by Dr. Elisabeth Fischer-Friedrich, group leader at the Excellence Cluster Physics of Life (PoL) and the Biotechnology Center TU Dresden (BIOTEC) studied how cancer cells are able to divide in a crowded tumor tissue and connected it to the hallmark of cancer progression and metastasis, the epithelial-mesenchymal transition (EMT).

How tumor cells evade the immune defense
Scientists are increasingly trying to use the body's own immune system to fight cancer.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

New pathway to attack tumor cells identified
A study led by the Institut de Neurociències (INc-UAB) describes a new strategy to tackle cancer, based on inducing a potent stress in tumor causing cell destruction by autophagy.

Nutrient deficiency in tumor cells attracts cells that suppress the immune system
A study led by IDIBELL researchers and published this week in the American journal PNAS shows that, by depriving tumor cells of glucose, they release a large number of signaling molecules.

Read More: Tumor Cells News and Tumor Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.